化合物WM-1119 | 2055397-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 化合物WM-1119
• 中文别名: 2-氟-N'-(3-氟-5-(吡啶-2-基)苯甲酰基)苯磺酰肼；化合物WM-1119
• 英文名称: WM-1119
• 英文别名: 2-fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide；2-Fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide；3-fluoro-N'-(2-fluorophenyl)sulfonyl-5-pyridin-2-ylbenzohydrazide
• CAS: 2055397-28-7
• 化学式: C₁₈H₁₃F₂N₃O₃S
• 分子量: 389.382
• InChiKey: QLXULUNLCRKWRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  化合物WM-1119 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以85%的产率得到2-(3-fluoro-5-(2-((2-fluorophenyl)sulfonyl)hydrazinecarbonyl)phenyl)pyridine 1-oxide
  参考文献：
  名称：

  Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents

  摘要：

  A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 mu M. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity relationship investigations, which resulted in the discovery of advanced compounds such as 55 and 80. These two compounds represent significant improvements on our recently reported prototypical lead WM-8014 (3) as they are not only equivalently potent as inhibitors of KAT6A but are less lipophilic and significantly more stable to microsomal degradation. Furthermore, during this process, we discovered a distinct structural subclass that contains key 2-fluorobenzenesulfonyl and phenylpyridine motifs, culminating in the discovery of WM-1119 (4). This compound is a highly potent KAT6A inhibitor (IC50 = 6.3 nM; K-D = 0.002 mu M), competes with Ac-CoA by binding to the Ac-CoA binding site, and has an oral bioavailability of 56% in rats.

  DOI：

  10.1021/acs.jmedchem.9b02071
• 作为产物：
  描述：

  2-氟苯磺酰氯 在 N-羟基-7-氮杂苯并三氮唑 、 hydrazine hydrate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.0h， 生成 化合物WM-1119
  参考文献：
  名称：

  Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents

  摘要：

  A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 mu M. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity relationship investigations, which resulted in the discovery of advanced compounds such as 55 and 80. These two compounds represent significant improvements on our recently reported prototypical lead WM-8014 (3) as they are not only equivalently potent as inhibitors of KAT6A but are less lipophilic and significantly more stable to microsomal degradation. Furthermore, during this process, we discovered a distinct structural subclass that contains key 2-fluorobenzenesulfonyl and phenylpyridine motifs, culminating in the discovery of WM-1119 (4). This compound is a highly potent KAT6A inhibitor (IC50 = 6.3 nM; K-D = 0.002 mu M), competes with Ac-CoA by binding to the Ac-CoA binding site, and has an oral bioavailability of 56% in rats.

  DOI：

  10.1021/acs.jmedchem.9b02071

文献信息

• [EN] KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT<br/>[FR] MÉTHODES ET COMBINAISONS D'INHIBITEURS DE KAT6 POUR LE TRAITEMENT DU CANCER
  申请人：PFIZER

  公开号：WO2022013369A1

  公开（公告）日：2022-01-20

  This invention relates to methods and combination therapies for treating cancer by administering a KAT6 inhibitor to a patient in need therof.

  本发明涉及通过向需要治疗的患者施用KAT6抑制剂来治疗癌症的方法和联合疗法。
• Aryl sulfonohydrazides
  申请人：MONASH UNIVERSITY

  公开号：US10829446B2

  公开（公告）日：2020-11-10

  Compound of formula I: wherein: A is selected from: (i) where RF1 is H or F; (ii) (iii) a N-containing C6 heteroaryl group; and B is where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.

  式 I 的化合物： 其中 A 选自 (i) 其中 RF1 为 H 或 F； (ii) (iii) 含 N 的 C6 杂芳基；以及 B 是 其中 X1 是 CRF2 或 N，其中 RF2 是 H 或 F；X2 是 CR3 或 N，其中 R3 选自 H、Me、Cl、F OMe；X3 是 CH 或 N；X4 是 CRF3 或 N，其中 RF3 是 H 或 F；其中 X1、X2、X3 和 X4 中只有一个或两个可以是 N；以及 R4 选自 I、任选取代的苯基、任选取代的 C5-6 杂芳基、任选取代的 C1-6 烷基和任选取代的 C1-6 烷氧基，它们可用于治疗通过抑制 MOZ 而改善的病症。
• ARYL SULFONOHYDRAZIDES
  申请人：MONASH UNIVERSITY

  公开号：US20180222857A1

  公开（公告）日：2018-08-09

  Compound of formula I: wherein: A is selected from: (i) where R F1 is H or F; (ii) (iii) a N-containing C 6 heteroaryl group; and B is where X 1 is either CR F2 or N, where R F2 is H or F; X 2 is either CR 3 or N, where R 3 is selected from H, Me, Cl, F OMe; X 3 is either CH or N; X 4 is either CR F3 or N, where R F3 is H or F; where only one or two of X 1 , X 2 , X 3 and X 4 may be N; and R 4 is selected from I, optionally substituted phenyl, optionally substituted C 5-6 heteroaryl; optionally substituted C 1-6 alkyl and optionally substituted C 1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.